Clinical Trials Browser

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Adrenal Gland Diseases, Adrenocortical Hyperfunction, Cushing Syndrome, Diabetes Mellitus, Type 2, Endocrine System Diseases, Hyperglycemia, Hypertension, Pathologic Processes, Glucose Intolerance, Adrenocortical Carcinoma

NCT05347979 2023-02-09

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Phase 1 Completed

30 enrolled

Cushing Syndrome, Neoplasms

NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Phase 1/2 Completed

85 enrolled 24 charts

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02804750 2019-10-15

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Phase 2 Completed

35 enrolled 13 charts

Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

Clinical Trials

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

GRADIENT

GRACE

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome